Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359231151845
Abstract: Individual response to immune checkpoint inhibitors (ICIs) is currently unpredictable in patients with melanoma. Recent findings highlight a striking improvement in the clinical outcomes of overweight/obese patients treated with ICIs, which seems driven, at least… read more here.
Keywords: treated nivolumab; nivolumab pembrolizumab; role; patients treated ... See more keywords
Experience of nivolumab and pembrolizumab in metastatic non-small cell lung cancer in routine clinical practice (mNSCLC.).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21227
Abstract: e21227Background: Pembrolizumab (P) in first line if PD-L1 expression > 50% (KEYNOTE-024) or nivolumab (N) in second line (CheckMate 017 and 057) improves overall survival compared to chemotherapy ... read more here.
Keywords: non small; metastatic non; experience nivolumab; nivolumab pembrolizumab ... See more keywords
Nivolumab and Pembrolizumab in advanced cutaneous melanoma : Results from real-life data in patients from France— Evaluation of use, current practices and medico economic approach.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e21009
Abstract: e21009 Background: In 2016, Nivolumab (N) and Pembrolizumab (P) have been registred for first line ECOG PS 0-1 adult patients with non-resecable or metastatic melanoma. The Brittany and Pays de la Loire Cancer Observatory has… read more here.
Keywords: nivolumab pembrolizumab; treatment; melanoma; line ... See more keywords
Comparison of the efficacy and toxicity of anti-PD-1 monoclonal antibodies (nivolumab versus pembrolizumab) in treatment of patients with metastatic melanoma.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e21514
Abstract: e21514 Background: Anti-programmed cell death-1 antibodies (anti-PD-1) have become a standard treatment option for melanoma patients. Currently, two anti-PD-1 antibodies are registered in the treatment of melanoma patients: nivolumab and pembrolizumab. Nivolumab is a human… read more here.
Keywords: melanoma; efficacy toxicity; treatment; nivolumab pembrolizumab ... See more keywords
Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15040489
Abstract: No evidence is available on the head-to-head comparison of clinical outcomes of patients treated with immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) in a real-world setting. We aimed to compare the… read more here.
Keywords: nivolumab pembrolizumab; pembrolizumab atezolizumab; effectiveness; second line ... See more keywords